CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park(Memorial Sloan Kettering Cancer Center), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center)
Cited by 398
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
|Nature Reviews Clinical Oncology|2019|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
|Scientific Reports|2017|397
GPRC5D-Targeted CAR T Cells for Myeloma
|New England Journal of Medicine|2022|383